tradingkey.logo

Lifecore Biomedical Inc

LFCR
查看詳細走勢圖
8.170USD
+0.130+1.62%
收盤 12/22, 16:00美東報價延遲15分鐘
306.10M總市值
虧損本益比TTM

Lifecore Biomedical Inc

8.170
+0.130+1.62%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.62%

5天

+3.68%

1月

+6.94%

6月

+17.72%

今年開始到現在

+9.96%

1年

+12.85%

查看詳細走勢圖

TradingKey Lifecore Biomedical Inc股票評分

單位: USD 更新時間: 2025-12-22

操作建議

Lifecore Biomedical Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名69/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價8.75。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Lifecore Biomedical Inc評分

相關信息

行業排名
69 / 158
全市場排名
176 / 4578
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 5 分析師
買入
評級
8.750
目標均價
+16.51%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Lifecore Biomedical Inc亮點

亮點風險
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
業績高增長
公司營業收入穩步增長,連續3年增長24.79%
業績轉虧
公司業績轉虧,最新年度虧損美元
估值低估
公司最新PE估值-7.86,處於3年歷史低位
機構減倉
最新機構持股28.27M股,環比減少2.63%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉2.60K股

Lifecore Biomedical Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Lifecore Biomedical Inc簡介

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
公司代碼LFCR
公司Lifecore Biomedical Inc
CEOJosephs (Paul)
網址https://www.lifecore.com/

常見問題

Lifecore Biomedical Inc(LFCR)的當前股價是多少?

Lifecore Biomedical Inc(LFCR)的當前股價是 8.170。

Lifecore Biomedical Inc 的股票代碼是什麼?

Lifecore Biomedical Inc的股票代碼是LFCR。

Lifecore Biomedical Inc股票的52週最高點是多少?

Lifecore Biomedical Inc股票的52週最高點是8.850。

Lifecore Biomedical Inc股票的52週最低點是多少?

Lifecore Biomedical Inc股票的52週最低點是4.760。

Lifecore Biomedical Inc的市值是多少?

Lifecore Biomedical Inc的市值是306.10M。

Lifecore Biomedical Inc的淨利潤是多少?

Lifecore Biomedical Inc的淨利潤為-44.36M。

現在Lifecore Biomedical Inc(LFCR)的股票是買入、持有還是賣出?

根據分析師評級,Lifecore Biomedical Inc(LFCR)的總體評級為買入,目標價格為8.750。

Lifecore Biomedical Inc(LFCR)股票的每股收益(EPS TTM)是多少

Lifecore Biomedical Inc(LFCR)股票的每股收益(EPS TTM)是-1.040。
KeyAI